A Report on a Relapsed Case of Lepromatous Leprosy, Resistant to DDS and RFP. The Time Course of Mycobacterial-Specific and Mycobacterium leprae Specific Antibody Levels During the Chemotherapy.

1996 ◽  
Vol 58 (2) ◽  
pp. 259-263 ◽  
Author(s):  
Masako NAMISATO ◽  
Akiko OBARA ◽  
Kunio KAWATSU ◽  
Shinzo IZUMI ◽  
Hideoki OGAWA
1980 ◽  
Vol 152 (5) ◽  
pp. 1302-1310 ◽  
Author(s):  
D S Pisetsky ◽  
G A McCarty ◽  
D V Peters

The quantitative expression of anti-DNA and anti-Sm antibodies has been investigated in autoimmune MRL-lpr/lpr and MRL-+/+ mice. Anti-Sm antibodies were detected in sera from 21/23 lpr/lpr and 10/16 +/+ mice, with individual animals showing striking variation in the time-course and magnitude of this autoantibody response. The peak antibody levels of the responding animals of each substrain did not differ significantly. For anti-DNA antibody, a different pattern of responsiveness was observed. Individual animals of each substrain produced very similar responses in terms of the magnitude and time-course of serum anti-DNA antibody. The differences in the peak levels of the two substrains were highly significant, with lpr/lpr mice demonstrating a much greater anti-DNA antibody response than +/+ mice. In lpr/lpr mice tested for both autoantibody systems, serum anti-DNA and anti-Sm antibodies showed distinct time-courses. These studies indicate that anti-DNA and anti-Sm antibodies are expressed independently in MRL mice, with the expression of anti-DNA, but not anti-Sm antibody markedly influenced by the presence of the 1pr gene. A fundamental difference in the mechanisms involved in the generation of anti-DNA and anti-Sm antibodies is suggested by the quantitative pattern of the two responses.


2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Richard Kwizera ◽  
Rosalind Parkes-Ratanshi ◽  
Iain D. Page ◽  
Christine Sekaggya-Wiltshire ◽  
Joseph Musaazi ◽  
...  

2007 ◽  
Vol 18 (4) ◽  
pp. 320-325 ◽  
Author(s):  
Metin Aydogan ◽  
Nihal Mete ◽  
Didem Yazi ◽  
Tunc Akkoc ◽  
Cevdet Ozdemir ◽  
...  

2020 ◽  
Vol 23 (8) ◽  
pp. 1026-1031
Author(s):  
N. S. Yudin ◽  
V. A. Belyavskaya ◽  
V. N. Maksimov ◽  
D. E. Ivanoshchuk ◽  
P. S. Orlov ◽  
...  

2011 ◽  
Author(s):  
Michael K Leonard Jr ◽  
Henry M Blumberg ◽  
Carlos Franco-Paredes

Mycobacterium leprae infection (i.e., leprosy) is a disease that has been recognized—and often misunderstood—since ancient times. The emergence of HIV/AIDS and the development of newer culture methodologies and molecular diagnostic tools have brought about increased interest in the epidemiology, diagnosis, and treatment of human infections from nontuberculous mycobacteria (NTM). More than 140 species of NTM have been identified; approximately 50 of these may be pathogenic for humans, causing a broad spectrum of disease. This chapter covers both M. leprae and selected NTM organisms, including M. avium complex; M. kansasii; M. marinum; and rapidly growing mycobacteria such as M. chelonae, M. fortuitum, and M. abscessus. The section on leprosy encompasses subsections on diagnosis, clinical manifestations and classification, laboratory studies, treatment, and leprosy reactions. Treatments for nontuberculous mycobacteria infections are also covered. Figures include a natural history of leprosy, tuberculoid leprosy, lepromatous leprosy, and various forms of borderline leprosy, as well as type 1 and type 2 leprosy reaction. Tables include the Ridley-Jopling classification of leprosy, recommendations for treatment of leprosy, clinical characteristics and treatment of leprosy, major clinical syndromes associated with nontuberculous mycobacterial infections, diagnosing nontuberculous mycobacterial lung disease, a listing of slow and rapidly growing mycobacteria that are human pathogens, plus treatment regimens for selected nontuberculous mycobacterial infections in adults. This review contains 59 references.


Sign in / Sign up

Export Citation Format

Share Document